Sign in Welcome! Log into your account your username your password Forgot your password? Get help Password recovery Recover your password your email A password will be e-mailed to you. HomeLatest Pharma-NewsAZ's NDA filing anticipated based on positive data from interim analysis Latest Pharma-News AZ’s NDA filing anticipated based on positive data from interim analysis By admin June 22, 2022 0 48 Share FacebookTwitterWhatsAppLinkedin Share FacebookTwitterWhatsAppLinkedin Previous articleFDA Announces Plans for Proposed Rule to Reduce Addictiveness of Tobacco ProductsNext articleNovartis Tabrecta receives EC approval for METex14 skipping advanced nSCLC RELATED ARTICLES Latest Pharma-News FDA Takes Steps to Ensure Safety of Cinnamon Products Sold in the US admin - March 8, 2024 Latest Pharma-News FDA Clears First Over-the-Counter Continuous Glucose Monitor admin - March 8, 2024 Latest Pharma-News FDA, Industry Actions End Sales of PFAS Used in US Food Packaging admin - March 1, 2024 LEAVE A REPLY Cancel reply Comment: Please enter your comment! Name:* Please enter your name here Email:* You have entered an incorrect email address! Please enter your email address here Website: Save my name, email, and website in this browser for the next time I comment. - Advertisment - Most Popular FDA Takes Steps to Ensure Safety of Cinnamon Products Sold in the US March 8, 2024 FDA Clears First Over-the-Counter Continuous Glucose Monitor March 8, 2024 FDA, Industry Actions End Sales of PFAS Used in US Food Packaging March 1, 2024 Regulatory Applications Accepted in the U.S. and Japan for BMS Breyanzi in Relapsed or Refractory FL and Relapsed or Refractory MCL February 3, 2024 Load more